The evolving use of measurable residual disease in chronic lymphocytic leukemia clinical trials

Measurable residual disease (MRD) status in chronic lymphocytic leukemia (CLL), assessed on and after treatment, correlates with increased progression-free and overall survival benefit. More recently, MRD assessment has been included in large clinical trials as a primary outcome and is increasingly...

Descripción completa

Detalles Bibliográficos
Autores principales: Fisher, A., Goradia, H., Martinez-Calle, N., Patten, PEM., Munir, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992794/
https://www.ncbi.nlm.nih.gov/pubmed/36910619
http://dx.doi.org/10.3389/fonc.2023.1130617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992794/
https://www.ncbi.nlm.nih.gov/pubmed/36910619
http://dx.doi.org/10.3389/fonc.2023.1130617

Ejemplares similares